Objective:

To investigate the efficacy of first-line combination therapies for advanced renal cell carcinoma (RCC) specifically in patients with favorable prognostic scores.

Approach:

Key Findings:

• Combination therapies show improved overall survival (OS) and progression-free survival (PFS) in intermediate and poor-risk groups.
• In favorable risk patients, combination therapies reduce disease progression risk but do not significantly improve OS compared to sunitinib.
• Monotherapy with TKIs remains a viable option for favorable risk patients due to the lack of significant OS improvement with combination therapies.

Interpretation:

While combination immunotherapy shows promise in advanced RCC, its benefits in favorable risk patients are limited, necessitating further research to optimize treatment strategies based on individual patient characteristics.

Limitations:

• Only included studies published in English, which may introduce language bias.
• Did not register the meta-analysis protocol in international registers.
• Potential biases in included studies may affect results.

Conclusion:

Combination immunotherapy approaches may not provide significant OS benefits for favorable risk patients compared to sunitinib, highlighting the need for personalized treatment strategies.

Source

Based on findings from:

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

Mattia Alberto Di Civita, Daniele Marinelli, Valerio Marco Michetti, Adele Artemi, Andrea Ballario, Andrea Torchia, Laura Pappalardo, Martina Pecoraro, Iolanda Speranza, Alessandro Sciarra, Valeria Panebianco, Michela Roberto, Daniele Santini. Bmc Cancer, 2026.

https://link.springer.com/article/10.1186/s12885-025-15462-5

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.